SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02311140

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms

The aim of the proposed trial in assessment of effects of Kalydeco™ treatment on sinonasal involvement in CF patients with at least one mutation of G551D receiving a new therapy with the CFTR potentiator. The focus will be given on changes in epithelial lining fluid inflammatory markers from CF upper airways sampled by nasal lavage. The program is subdivided into a part A assessing inflammatory markers in NL and sinonasal symptoms longitudinally from pre-treatment to months with the new therapy. Part B will only be performed in a smaller subgroup and assess inflammatory markers in NL every second day in the first month of treatment and then every week until the end of month 3 with Kalydeco™ therapy.

NCT02311140 Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco
MeSH: Inflammation Sinusitis
HPO: Sinusitis

1 Interventions

Name: nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms

Type: Other

Cystic Fibrosis patients with G551D mutation


Primary Outcomes

Measure: Changes in concentration of inflammatory markers

Time: 3 yrs

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 G551D

Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms The aim of the proposed trial in assessment of effects of Kalydeco™ treatment on sinonasal involvement in CF patients with at least one mutation of G551D receiving a new therapy with the CFTR potentiator. --- G551D ---

Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco Inflammation Sinusitis null --- G551D ---

Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco Inflammation Sinusitis null --- G551D --- --- G551D ---

Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco Inflammation Sinusitis null --- G551D --- --- G551D --- --- G551D ---

Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco Inflammation Sinusitis null --- G551D --- --- G551D --- --- G551D --- --- G551D ---

Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inclusion Criteria: - G551D and Kalydeco therapy Exclusion Criteria: - no G551D Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco Inflammation Sinusitis null --- G551D --- --- G551D --- --- G551D --- --- G551D --- --- G551D ---



HPO Nodes


HPO:
Sinusitis
Genes 89
CYBB BLM DNAAF2 UNC119 DNAAF5 DNAAF3 DNAI1 TCF3 SPAG1 CFAP300 PRTN3 ICOS RNF168 FMR1 WAS CCDC103 MGP WIPF1 CD19 RSPH4A USB1 ZMYND10 RSPH1 CIITA FCGR3A HLA-DPA1 DOCK8 HLA-DPB1 DNAAF4 CXCR4 PIK3R1 CCDC114 RFXANK IGHM ACP5 CYBC1 BTK IL21R NFKB2 NCF1 PSMB4 DNAI2 BLNK IRF8 PSMB9 TNFRSF13C LRRC8A TNFRSF13B NBN DRC1 CD79A CD79B PIH1D3 PTPN22 NCF2 NCF4 TTC25 CTLA4 IL17RA IGLL1 RPGR LRRC6 ATM DNAL1 ARMC4 LRBA RUNX2 IKBKB DNAAF1 CFI ADA CR2 CCDC65 IL2RG RFX5 RFXAP TAP1 TAP2 CFAP298 TAPBP RSPH9 CCDC39 HYDIN NME8 IGSF3 PNP CCDC40 DNMT3B CYBA